Similar articles for PMID: 32086713

Year	Number of Results
2011	1
2012	6
2013	12
2014	14
2015	16
2016	16
2017	21
2018	31
2019	25
2020	18
2021	31
2022	25
2023	6
2024	0

1

Italian real-life clinical setting: the persistence and adherence with mirabegron in women with overactive bladder.

Illiano E, Finazzi Agrò E, Natale F, Balsamo R, Costantini E. Illiano E, et al. Int Urol Nephrol. 2020 Jun;52(6):1035-1042. doi: 10.1007/s11255-020-02412-2. Epub 2020 Feb 21. Int Urol Nephrol. 2020. PMID: 32086713

2

Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review.

Yeowell G, Smith P, Nazir J, Hakimi Z, Siddiqui E, Fatoye F. Yeowell G, et al. BMJ Open. 2018 Nov 21;8(11):e021889. doi: 10.1136/bmjopen-2018-021889. BMJ Open. 2018. PMID: 30467131 Free PMC article.

3

Persistence in the treatment of overactive bladder syndrome (OAB) with mirabegron in a multicenter clinical study.

Martan A, Masata J, Krhut J, Zachoval R, Hanus T, Svabik K. Martan A, et al. Eur J Obstet Gynecol Reprod Biol. 2017 Mar;210:247-250. doi: 10.1016/j.ejogrb.2016.12.030. Epub 2016 Dec 23. Eur J Obstet Gynecol Reprod Biol. 2017. PMID: 28073038

4

The impact of Mirabegron on sexual function in women with idiopathic overactive bladder.

Gubbiotti M, Giannantoni A, Cantaluppi S, Coluccia AC, Ghezzi F, Serati M. Gubbiotti M, et al. BMC Urol. 2019 Jan 21;19(1):7. doi: 10.1186/s12894-019-0438-8. BMC Urol. 2019. PMID: 30665388 Free PMC article.

5

[Persistence in the treatment of overactive bladder (OAB) with Mirabegron in a multicentre clinical study].

Martan A, Mašata J, Švabík K, Hanuš T, Krhut J. Martan A, et al. Ceska Gynekol. 2015 Aug;80(4):244-8. Ceska Gynekol. 2015. PMID: 26265411 Czech.

6

Effectiveness and persistence of mirabegron as a first-line treatment in patients with overactive bladder in real-life practice.

Shin JH, Choo MS. Shin JH, et al. Low Urin Tract Symptoms. 2019 May;11(3):151-157. doi: 10.1111/luts.12253. Epub 2019 Jan 8. Low Urin Tract Symptoms. 2019. PMID: 30623583

7

Third-line treatment for overactive bladder: should mirabegron be tried before intravesical botulinum toxin A therapy?

Balachandran A, Curtiss N, Basu M, Duckett J. Balachandran A, et al. Int Urogynecol J. 2015 Mar;26(3):367-72. doi: 10.1007/s00192-014-2462-2. Epub 2014 Jul 17. Int Urogynecol J. 2015. PMID: 25030325

8

[Degree of satisfaction of patients continuing overactive bladder treatment with mirabegron].

Švabík K, Mašata J, Krhut J, Zachoval R, Hanuš T, Halaška M, Horčička L, Krofta L, Hanáková M, Martan A. Švabík K, et al. Ceska Gynekol. 2017 Winter;82(1):48-52. Ceska Gynekol. 2017. PMID: 28252310 Czech.

9

Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).

Yamaguchi O, Kakizaki H, Homma Y, Igawa Y, Takeda M, Nishizawa O, Gotoh M, Yoshida M, Yokoyama O, Seki N, Okitsu A, Hamada T, Kobayashi A, Kuroishi K. Yamaguchi O, et al. BJU Int. 2015 Oct;116(4):612-22. doi: 10.1111/bju.13068. Epub 2015 Apr 23. BJU Int. 2015. PMID: 25639296 Clinical Trial.

10

Critical analysis of phase II and III randomised control trials (RCTs) evaluating efficacy and tolerability of a β₃-adrenoceptor agonist (Mirabegron) for overactive bladder (OAB).

Rossanese M, Novara G, Challacombe B, Iannetti A, Dasgupta P, Ficarra V. Rossanese M, et al. BJU Int. 2015 Jan;115(1):32-40. doi: 10.1111/bju.12730. Epub 2014 Jul 27. BJU Int. 2015. PMID: 24602031 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

175 results

Results by year